Compare NUVB & FRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NUVB | FRPT |
|---|---|---|
| Founded | 2018 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Packaged Foods |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.4B |
| IPO Year | N/A | 2014 |
| Metric | NUVB | FRPT |
|---|---|---|
| Price | $8.98 | $61.05 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 15 |
| Target Price | $10.63 | ★ $77.07 |
| AVG Volume (30 Days) | ★ 6.1M | 1.2M |
| Earning Date | 11-03-2025 | 02-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 169.38 |
| EPS | N/A | ★ 2.38 |
| Revenue | $26,748,000.00 | ★ $1,079,494,000.00 |
| Revenue This Year | $609.55 | $15.47 |
| Revenue Next Year | $197.91 | $9.68 |
| P/E Ratio | ★ N/A | $25.23 |
| Revenue Growth | ★ 1137.19 | 16.34 |
| 52 Week Low | $1.54 | $46.76 |
| 52 Week High | $9.75 | $164.07 |
| Indicator | NUVB | FRPT |
|---|---|---|
| Relative Strength Index (RSI) | 61.71 | 48.79 |
| Support Level | $8.84 | $62.23 |
| Resistance Level | $9.75 | $64.90 |
| Average True Range (ATR) | 0.43 | 2.14 |
| MACD | -0.11 | -0.67 |
| Stochastic Oscillator | 56.50 | 18.85 |
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.
Freshpet produces and sells premium fresh pet food through its company-owned refrigerators placed in grocery, mass and club, pet specialty, and natural stores. Freshpet primarily targets dogs (96% of 2024 sales), with cats and treats comprising the rest of its sales. Geographically, the company's home US market, where all its food is produced, accounts for about 98% of sales, with exports to Canada, the United Kingdom, and other European countries accounting for the remaining balance.